Risk factors for anthracycline-associated cardiotoxicity

被引:0
作者
Raquel E. Reinbolt
Roshan Patel
Xueliang Pan
Cynthia Dawn Timmers
Robert Pilarski
Charles L. Shapiro
Maryam B. Lustberg
机构
[1] The Ohio State University Comprehensive Cancer Center and the Stefanie Spielman Comprehensive Breast Center,The Breast Program
[2] The Ohio State University College of Medicine,Center for Biostatistics
[3] The Ohio State University Comprehensive Cancer Center,Division of Human Genetics
[4] The Ohio State University Comprehensive Cancer Center,undefined
[5] The Ohio State University Comprehensive Cancer Center,undefined
来源
Supportive Care in Cancer | 2016年 / 24卷
关键词
Anthracycline; Cardiotoxicity; CBR; Trastuzumab; Single nucleotide polymorphisms;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2173 / 2180
页数:7
相关论文
共 270 条
[1]  
Buzdar AU(1985)Early and delayed clinical cardiotoxicity of doxorubicin Cancer 55 2761-2765
[2]  
Marcus C(2003)Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2869-2879
[3]  
Smith TL(1998)Doxorubicin-induced cardiomyopathy N Engl J Med 339 900-905
[4]  
Blumenschein GR(2001)Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study J Clin Oncol: Off J Am Soc Clin Oncol 19 191-196
[5]  
Swain SM(1979)Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 710-717
[6]  
Whaley FS(2004)Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the north central cancer treatment group N9831 intergroup adjuvant trial J Clin Oncol: Off J Am Soc Clin Oncol 22 3700-3704
[7]  
Ewer MS(2007)Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation Int J Nanomed 2 567-583
[8]  
Singal PK(2005)Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study J Clin Oncol: Off J Am Soc Clin Oncol 23 8597-8605
[9]  
Iliskovic N(2010)Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 56 1644-1650
[10]  
Kremer LC(2011)HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies Exp Rev Anticancer Ther 11 263-275